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Abstract 
 
During the last decade, peroxisome proliferator-activated receptor δ (PPARδ) has received 
great attention as a potential drug target for the prevention of the metabolic syndrome and 
type 2 diabetes. The beneficial biological effects of PPARδ activation are well established, 
and increases in the amount of high-density lipoprotein (HDL) and reverse cholesterol 
transport, as well as a decrease in plasma glucose. However, much remains to be discovered, 
and to date, there are no drugs on the market targeting this receptor.  
Due to the beneficial effects of PPARδ activation, it is also of interest to investigate the 
effects of PPARδ antagonism, in order to further elucidate the biological role of PPARδ. This 
thesis therefore focused on the development of new high-affinity PPARδ antagonists.         
In total, eleven compounds were prepared using GSK3787, a selective PPARδ antagonist, as 
the lead compound. The first-generation analogues, 7-16, were synthesized partly by a 
published route. An efficient approach was developed for the synthesis of the second-
generation analogue 23. Molecular modelling studies indicate that 23 is the most potent of the 
synthesized compounds. Biological studies are currently ongoing. 
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PTSA p-toluenesulfonic acid 
SAR structure-activity relationship 
THF tetrahydrofuran 
TMS 
TMS 
trimethylsilyl 
VLDL very low density lipoprotein 
 
 
XII 
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
XIII 
Table of contents 
 
Acknowledgements .................................................................................................................. V 
Abstract ................................................................................................................................. VII 
Graphical abstract .................................................................................................................. IX 
List of abbreviations ............................................................................................................... XI 
Table of contents .................................................................................................................. XIII 
1 Introduction ........................................................................................................................ 1 
1.1 Obesity, type 2 diabetes and the metabolic syndrome ............................................. 1 
1.2 Nuclear receptors ........................................................................................................ 2 
1.2.1 Peroxisome proliferator-activated receptors ........................................................... 2 
1.2.2 Structural features ................................................................................................... 2 
1.2.3 PPAR tissue distribution and biological effects ..................................................... 4 
1.3 Endogenous ligands ..................................................................................................... 5 
1.4 Synthetic ligands in clinical use ................................................................................. 5 
1.5 PPARδ as a therapeutic target ................................................................................... 7 
1.5.1 PPARδ and its effects in skeletal muscle ................................................................ 7 
1.5.2 PPARδ and its effects in adipose tissue .................................................................. 9 
1.5.3 PPARδ and its effects in the liver ........................................................................... 9 
1.5.4 The toxicological effects of PPARδ ....................................................................... 9 
1.5.5 Current PPARδ agonists ....................................................................................... 10 
1.5.6 PPARδ antagonism ............................................................................................... 10 
1.6 Identification of GSK3787 ........................................................................................ 14 
1.7 Aim of thesis .............................................................................................................. 15 
2 Results and discussions .................................................................................................... 17 
2.1 Background for the first-generation analogues of GSK3787 ................................ 17 
2.2 Synthesis of first-generation analogues 7-16 .......................................................... 17 
2.3 Attempted synthesis of first-generation analogues ................................................ 20 
2.4 A second-generation analogue of GSK3787 ............................................................ 21 
2.5 Attempted syntheses of N-methyl analogue 23 ....................................................... 23 
 
 
XIV 
2.5.1 The first approach ................................................................................................. 23 
2.5.2 The second approach ............................................................................................ 23 
2.5.3 The third approach ................................................................................................ 25 
2.5.4 The fourth approach .............................................................................................. 26 
2.5.5 The fifth approach: a direct N-alkylation .............................................................. 27 
2.5.6 The sixth approach ................................................................................................ 27 
2.6 Successful synthesis of the N-methyl analogue 23 .................................................. 29 
2.7 Alternative synthesis of compound 23 ..................................................................... 30 
2.8 Molecular modelling ................................................................................................. 31 
3 Conclusion and future work ........................................................................................... 33 
4 Spectroscopic elucidation and characterization of compounds ................................... 35 
4.1 General characterization of intermediates and analogues .................................... 35 
4.2 Spectroscopic characterization of first-generation analogues 7-16 and their 
intermediates 4-6 ................................................................................................................ 36 
4.2.1 Characterization of compound 4 ........................................................................... 36 
4.2.2 Characterization of compound 5 ........................................................................... 37 
4.2.3 Characterization of compound 6 ........................................................................... 38 
4.2.4 Characterization of compound 7 ........................................................................... 39 
4.2.5 Characterization of compound 8 ........................................................................... 40 
4.2.6 Characterization of compound 9 ........................................................................... 41 
4.2.7 Characterization of compound 10 ......................................................................... 42 
4.2.8 Characterization of compound 11 ......................................................................... 43 
4.2.9 Characterization of compound 12 ......................................................................... 44 
4.2.10 Characterization of compound 13 ....................................................................... 45 
4.2.11 Characterization of compound 14 ....................................................................... 46 
4.2.12 Characterization of compound 15 ....................................................................... 47 
4.2.13 Characterization of compound 16 ....................................................................... 48 
4.3 Spectroscopic characterization of the second-generation analogue 23 and its 
intermediates 48-49 ............................................................................................................ 49 
4.3.1 Characterization of compound 48 ......................................................................... 49 
4.3.2 Characterization of compound 49 ......................................................................... 50 
4.3.3 Characterization of compound 23 ......................................................................... 51 
4.4 Spectroscopic characterization of compounds from attempted approaches ....... 52 
 
 
XV 
4.4.1 Characterization of intermediates from the sixth approach .................................. 52 
5 Experimental section ....................................................................................................... 55 
5.1 General ....................................................................................................................... 55 
5.2 First-generation analogues ....................................................................................... 55 
5.2.1 Synthesis of intermediates .................................................................................... 55 
5.2.2 General procedure for the synthesis of first-generation analogues ...................... 56 
5.3 Second-generation analogue ..................................................................................... 60 
5.3.1 Synthesis of intermediates .................................................................................... 60 
5.3.2 Synthesis of the second-generation analogue ....................................................... 61 
5.4 Synthesis of intermediates from the sixth approach .............................................. 62 
References ............................................................................................................................... 65 
6 Appendix ........................................................................................................................... 67 
6.1 Spectra of prepared analogues and their intermediates ........................................ 67 
6.2 Spectra of intermediates from attempted approaches ........................................... 97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XVI 
 
 
 
1 
1 Introduction 
1.1 Obesity, type 2 diabetes and the metabolic syndrome 
Obesity is a health condition in which the proportion of body fat is abnormal or in great 
excess. It is a major risk factor for other conditions such as hypertension, dyslipidemia, 
insulin resistance and glucose intolerance [1]. These disorders, when occurring together, are 
known as the metabolic syndrome [2]. Furthermore, this cluster of metabolic disorders will 
increase the risk of cardiovascular diseases and type 2 diabetes [1].  
Insulin is an important peptide hormone involved in the complex pathophysiology of the 
metabolic syndrome, as it stimulates the cellular uptake and storage of glucose, thus 
decreasing blood glucose. It is secreted from β-cells in the islets of Langerhans in the 
pancreas, in response to elevated blood glucose concentration. Insulin exercises its metabolic 
effects in the liver, adipose tissue and muscle, where its overall function is to regulate the 
uptake of glucose, fatty acids and fat, which subsequently become stored as the fundamental 
fuel for all cell activity [3]. If insulin resistance exists, the liver, adipose tissue and muscle 
cells will fail to respond correctly to insulin. As a result, more insulin needs to be secreted by 
the pancreas in order to ensure glucose uptake by cells. Eventually, if this compensatory 
increase of insulin fails to occur, blood glucose concentrations will elevate, increasing the risk 
of developing type 2 diabetes [4].   
Furthermore, insulin resistance can lead to an unfavourable lipid profile, with high levels of 
very low-density lipoprotein (VLDL) and low levels of high-density lipoprotein (HDL) [4]. 
VLDL are particles containing cholesterol and newly synthesized triglycerides, and are 
responsible for transporting triglycerides from the liver to muscle and adipose tissue. During 
this process, the particles with the remaining cholesterol are converted to the low-density 
lipoprotein (LDL), which transports cholesterol into the cell membrane and are highly 
associated with the progression of atherosclerosis. Unlike LDL, HDL adsorbs cholesterol 
derived from cell breakdown in tissues, such as the arteries, and aids it back to the liver for 
excretion. Therefore, HDL is a key factor in reverse cholesterol transport and commonly 
referred to as the “good cholesterol” [5].  
Since 1980, worldwide obesity has more than doubled. Figures from 2008 classify 
approximately 1.5 billion adults as overweight. Today, obesity and overweight are the fifth 
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leading causes of death worldwide, resulting in 2.8 million deaths every year. According to 
the World Health Organization (WHO), more than 311 million people worldwide suffer from 
type 2 diabetes. This number is expected to more than double by 2030, due to increased 
obesity and sedentary lifestyle [6]. 
With this increasing health problem in mind, new and improved ways to prevent obesity and 
also type 2 diabetes, are in urgent need. More knowledge and understanding of the metabolic 
syndrome, and the biological functions, as well as new drugs are needed. Peroxisome 
proliferator-activated receptors (PPARs), and in particular the δ-subtype, have gained 
attention due to their role in ameliorating the metabolic disorders mentioned above [2].  
 
1.2 Nuclear receptors 
1.2.1 Peroxisome proliferator-activated receptors 
Peroxisome proliferator-activated receptors (PPARs) are a group of three ligand-activated 
transcription factors belonging to a superfamily of nuclear hormone receptors related to the 
retinoid, steroid and thyroid hormone receptors [7]. The PPARs were originally identified as 
orphan receptors owing to the lack of known endogenous ligands. Later, it was shown that 
these receptors are activated by endogenous fatty acids and eicosanoids, and that they regulate 
the transcriptions of various genes affecting the lipid and glucose homeostasis [7-9].  
To date, there are three identified subtypes in humans; PPARα (NR1C1), PPARδ (NR1C2) 
and PPARγ (NR1C3). They are expressed to a various degree in different tissues and exert 
distinct biological effects and ligand specificity [7, 10].  
1.2.2 Structural features 
All nuclear receptors show similar structural features and are composed of four distinct 
domains (Figure 1) [8, 11].  
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Figure 1. Functional domains of PPARs. The figure is not representable for the actual size of the various 
domains. 
 
The identified domains are A/B, C, D and E/F. The ligand-independent activation function 1 
(AF-1), located at the A/B domain, is the site of phosphorylation in the PPARs, common to 
all nuclear receptors. Next to A/B is the DNA binding domain (DBD) C, which interacts with 
peroxisome proliferator response elements (PPREs). These elements are constructed of 
hexanucleotides with the distinct sequence “AGGTCAnAGGTCA”, where the “n” is a single 
nucleotide spacer. Domain D contains a hinge region where the cofactors are docked [8, 11]. 
Cofactors control the gene transcription, and the recruitment of these cofactors can either 
induce transcription (coactivators) or actively repress it (corepressors) (Figure 2) [12]. 
 
 
Figure 2. Gene transcription induced by PPARs [8]. 
 
The final domain at the C-terminal is the E/F domain consisting of a ligand-binding domain 
(LBD), including the ligand-dependent activation function 2 (AF-2). The LBD is involved in 
the heterodimerization with the retinoid X receptor (RXR), while AF-2 is responsible for the 
recruitment of cofactors, which are crucial for regulating gene transcription [8, 11].  
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1.2.3 PPAR tissue distribution and biological effects  
The first receptor to be identified, named PPARα, was found to be expressed mainly in the 
heart, liver, skeletal muscle, kidney and intestine, but also in vascular cells, such as 
endothelial cells and monocytes/macrophages [8]. Its major role is to regulate the catabolism 
of fatty acids, by increasing β-oxidation of fatty acids, gluconeogenesis and ketone body 
synthesis [13].  
PPARγ is highly expressed in adipocytes, but is also found in other cell types such as 
epithelial cells of the intestine and specific kinds of immune and inflammatory cells. PPARγ 
enhances biological functions, which regulate adipogenesis, resulting in both adipocyte 
differentiation and an increase in small insulin-sensitive adipocytes [8]. In addition, PPARγ is 
involved in lipid metabolism by maintaining the adipocyte-specific functions [9]. 
Experimental studies suggest that the activation of PPARγ increase insulin sensitivity by 
affecting various genes in the glucose metabolism. Beneficial limiting processes of 
inflammation and atherosclerosis have also been reported [8, 14].   
PPARδ is ubiquitously expressed with high levels in heart, adipose tissue, skin and in skeletal 
muscle, where the relative expression of PPARδ is 10- and 50-fold higher compared to 
PPARα and PPARγ, respectively. Given that skeletal muscles comprise the largest organ in 
the body, the expression of PPARδ here may play an important physiological role with 
respect to the metabolic syndrome [10]. PPARδ is involved in numerous biological functions, 
such as lipid and glucose homeostasis, cell differentiation, proliferation, apoptosis and 
immune regulation [8, 13, 15]. It is established that PPARδ agonists may be effective in the 
treatment of the metabolic syndrome by increasing both HDL-cholesterol level and reverse 
cholesterol transport. This effect elevates the level of “good cholesterol” and reduces the 
amount of peripheral cholesterol by transporting it back to the liver for excretion, and hence 
preventing atherosclerosis. In addition, the benefits of PPARδ activation on atherosclerosis 
have been reported as a consequence of its suppression of cytokine expression, and thus 
inflammatory response [7]. Furthermore, activation of PPARδ in skeletal muscle and adipose 
tissue induces energy expenditure [9, 16]. Overall, it seems that activation of PPARδ has 
beneficial effects in regulating the metabolic syndrome. 
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1.3 Endogenous ligands  
PPARs have affinity for fatty acid-like molecules. Due to their hydrophobic ligand-binding 
pocket, it is not surprising that PPARs are activated by various fatty acids and eicosanoids, 
such as leukotrienes and prostaglandins, including PGA1 and PGD2  (Figure 3) [17]. 
According to current literature, PPARδ also binds different saturated and unsaturated fatty 
acids such as palmitic acid and linolenic acid [12]. However, to activate PPARδ, these ligands 
would need to be present at high concentrations (in the micromolar range) and they are not 
always selective for the δ-subtype [18].  
 
 
Figure 3. Structures of two prostaglandins, which are endogenous PPARδ ligands. 
 
1.4  Synthetic ligands in clinical use 
To date, the only available drugs activate the α- or the γ-subtype. PPARα activity can be 
modulated by a family of molecules called fibrates. These ligands were found to increase both 
VLDL and LDL-cholesterol with a following decrease of HDL-cholesterol. As mentioned in 
section 1.1, high levels of LDL are associated with increased risk of cardiovascular disease 
[4]. However, gemfibrozil (e.g. Lopid®) and fenofibrate (e.g. TriCor®) (Figure 4) are 
agonists in clinical use for reducing the cholesterol of patients at high risk of cardiovascular 
disease [14]. In Norway, marketing authorisations have not been issued for neither 
gemfibrozil nor fenofibrate, suggesting an unsatisfactory positive risk-benefit profile, and 
they are thus only available to Norwegian patients for compassionate use [19].  
 
PGA1
O
HO
OH
HOOC
PGD2
O
HOOC
OH
 
 
6 
 
Figure 4. Synthetic PPARα agonists (the fibrates) used in the treatment of hypertriglyceridemia. The EC50-value 
is taken from reference [20]. 
 
PPARγ is activated by the thiazolidinediones (TZDs) (Figure 5), which act as insulin 
sensitizers by reducing plasma glucose. Consequently, the TZDs are used in the treatment of 
type 2 diabetes. Troglitazone (e.g. ReZulin®) was the first substance to be marketed, but was 
withdrawn from the market as a result of idiosyncratic liver failures [14]. Rosiglitazone (e.g. 
Avandia®), belonging to the same class of drugs, has either been withdrawn from the market 
or sale has been restricted, due to increased risk of myocardial infarction [21, 22]. A third 
substance to be clinically used for the treatment of type 2 diabetes, namely pioglitazone (e.g. 
Actos®), is still marketed even though it may cause bladder tumours. However, this is not 
well-established [19]. 
 
 
Figure 5. Synthetic PPARγ agonists (TZDs). The EC50-values are taken from reference [20]. 
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1.5 PPARδ as a therapeutic target 
Nuclear receptors, and among them PPARδ has gained more attention during the past 10-15 
years. Its role as an important regulator in glucose and lipid homeostasis is established, 
especially in skeletal muscle, but also in adipose tissue and the liver. PPARδ is therefore an 
interesting biological target in the research fields of the metabolic syndrome and type 2 
diabetes. Despite research efforts, this receptor subtype remains the most poorly characterized 
and no synthetic ligands are yet developed for clinical use [23].  
1.5.1 PPARδ and its effects in skeletal muscle  
PPARδ plays an important role in skeletal muscle where it is expressed at 10- and 50-fold 
higher levels than PPARα and PPARγ, respectively. Skeletal muscle is made up of different 
fiber types with distinct metabolic and contractile characteristics. They are classified in three 
isoforms: oxidative slow-twitch (type I), mixed oxidative/glycolytic fast-twitch (type IIA) and 
glycolytic fast-twitch (type IIb) [10, 16, 24]. Oxidative slow-twitch fibers provide insulin-
stimulated glucose transport as they contain more glucose transporters and insulin signaling 
intermediates. Thus, it is evident that high amounts of slow-twitch oxidative fibers are 
favourable in terms of improving the insulin sensitivity [11].     
In addition, mitochondria, which oxidize fatty acids, are also found to be more abundantly 
expressed in oxidative slow-twitch fibers, increasing their potential for oxidation of fatty 
acids. For lipid catabolism to occur, the plasma-free fatty acids must penetrate the cell 
membrane by either diffusion or via receptor proteins, such as CD36 (Figure 6). In cytosol 
they react with CoA or ATP to form fatty acyl-CoA complexes, before entering the 
mitochondria, facilitated by carnityl palmitoyl transferase. Once inside the mitochondria, the 
free fatty acids can be oxidized [25]. PPARδ is an important regulator of lipid catabolism, a 
process that mainly occurs in skeletal muscle. A number of genes involved in the regulation 
of cellular energy expenditure towards the use of fat as an energy source are PPARδ-
dependent, such as PDK4, which reduces glucose oxidation and thereby enhances lipid 
oxidation [26, 27]. This explains why PPARδ activation has protective effects against the 
consequences of dietary lipid overload [28].  
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Figure 6. Decreased glucose oxidation in mitochondria and increased lipid oxidation, as a result of a change in 
gene expression governed by PPARδ [11]. 
 
The increased lipid catabolism due to activation of PPARδ may also indicate that PPARδ alter 
skeletal muscle glucose uptake. However, experimental studies show varying results and 
further studies designed to examine the effects of PPARδ-specific agonists on skeletal muscle 
glucose uptake are warranted [11].       
Since PPARδ is mainly expressed in slow-twitch oxidative fibers, it has also been proposed to 
play a role in fiber-type regulation. Overexpression of PGC1a, an important gene in fiber-type 
regulation (a coactivator of PPARδ), promoted a full transformation of fast-twitch to slow-
twitch muscle fibers in mice [29]. Furthermore, an activation of PPARδ or inhibition of the 
corepressor RIP140 also favours the formation of slow-twitch muscle fibers in a similar 
manner [29, 30]. Interestingly, it was also found that PPARδ overexpression mediates 
comparable biological effects as those induced by physical activity. Conversion of muscle 
fibers has also been discovered in humans as a result of endurance training. This raises the 
question of whether PPARδ activation can mimic the beneficial effects of physical activity 
[31, 32].  
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1.5.2 PPARδ and its effects in adipose tissue 
As mentioned in the previous section, elevated proportions of slow-twitch fibers in skeletal 
muscle are found to increase the amount of PPARδ receptors, leading to an increase in the 
uptake of fatty acids. As a result, lipid storage in adipocytes can be avoided [28], thus also 
obesity-induced insulin resistance. In addition, an expansion of adipocytes in a given tissue, 
which is often seen in connection to visceral obesity, may result in the recruitment of 
macrophages, which subsequently increases the production of cytokines. Cytokine-induced 
inflammation is implicated in the pathogenesis of insulin resistance [33, 34], as well as 
atherosclerosis. Consequently, the amount of macrophages is believed to correlate with the 
degree of insulin resistance. PPARδ activation is suggested to be important in this 
pathophysiology by attenuating the production of inflammatory cytokines and is thus an 
important target for the prevention of insulin resistance [34]. 
1.5.3 PPARδ and its effects in the liver 
Based on the findings reported by Lee and co-workers, PPARδ activation in liver has been 
suggested to ameliorate glucose tolerance and insulin sensitivity. Experiments have shown 
PPARδ knockout mice to be glucose intolerant, whereas treatment of diabetic leptin-resistent 
(db/db) mice with a PPARδ agonist, improved both insulin sensitivity and glucose tolerance. 
Decreased hepatic glucose output has been observed as a result of increased synthesis of fatty 
acids in the liver, the same metabolic effect as induced in skeletal muscle by exercise, fasting 
or cold exposure [7, 35, 36]. Furthermore, a recent study, reported by Serrano-Marco et al., 
describes PPARδ-mediated inhibition of proteins in the liver, which consequently leads to the 
prevention of cytokine-induced insulin resistance [37].  
1.5.4 The toxicological effects of PPARδ 
Due to the wide tissue distribution of PPARδ, toxicity and potential side effects of drug 
candidates have to be taken into account. Experiments with genetic mouse models for 
colorectal and intestinal cancer have shown results of increased polyp formation, indicating 
that PPARδ may be involved in the up-regulation of intestinal adenoma growth [9]. Other 
investigations report the opposite results, claiming that PPARδ attenuates polyp formation. 
Additionally, it is suggested that PPARδ antagonists inhibit carcinogenesis in some tissues. In 
order to use agonists in the treatment of metabolic syndrome, it is clear that this topic needs 
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extensive research. More knowledge about the relationship of PPARδ and carcinogenesis will 
aid the understanding of side effects of drug candidates [38]. 
1.5.5 Current PPARδ agonists 
PPARδ agonists are currently not used clinically, despite the positive effects of PPARδ 
activation. The identification of GW501516 (EC50 = 1.1 nM) and GW0742 (EC50 = 1.0 nM) 
as selective and potent PPARδ agonists has been an important contribution to the 
investigation of the biological roles of the PPARδ subtype (Figure 7) [39].  
 
 
Figure 7. Structures of two synthetic PPARδ agonists. 
 
1.5.6 PPARδ antagonism 
The beneficial physiological effects of agonism in PPARδ, especially in alleviating the 
symptoms of the metabolic syndrome, are well established [11, 40]. However, to date, there 
are no drugs available on the market targeting PPARδ, owing partly to the fact that much 
remains to be discovered about the biological roles of this receptor. Recently, the focus has 
been extended to the development of PPARδ antagonists, since the investigation of PPARδ 
antagonism is of equal importance to the elucidation of the biological roles of PPARδ.  
There is a need for new molecules serving as pharmacological tools that enable the 
investigation of specific physiological functions governed by PPARδ. In this context, the 
development of new high-affinity PPARδ-selective antagonists can aid the understanding of 
the physiological effects of repression of the PPARδ gene program. Given that antagonistic 
modulation of PPARs is indicated in both pro-inflammatory and obesogenic [41] 
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physiological responses, the synthesis of new antagonists to further elaborate on the 
mechanism behind these effects, is desirable.  
 
Previously published inhibitors of PPARδ  
In 2008, a research group from GlaxoSmithKline (GSK) published GSK0660 (IC50 = 300 nM) 
as the first PPARδ antagonist to be discovered (Figure 8). It was identified in a high-
throughput screen and was found to be selective for the δ-subtype. Unfortunately, the oral 
bioavailability was rather poor [40].  
Later, in 2009, the same research group identified GSK3787 (Figure 8), a selective and potent 
PPARδ antagonist (IC50 = 126 nM) with enhanced bioavailability. This compound, with its 
electrophilic site para to the electron-withdrawing trifluoromethyl group (see Figure 8), is 
suggested to bind covalently with a nucleophilic cysteine residue within the LBD of the 
PPARδ receptor [42].  
 
 
Figure 8. Structures of two synthetic PPARδ antagonists. 
 
The antagonistic effects of GSK3787 were studied in human skeletal muscle cells in the 
presence of an agonist (GW0742). GK3787 was found to antagonize the agonist-induced gene 
transcription of two important PPARδ genes, namely CPT1a and PDK4. These genes are 
involved in fatty acid β-oxidation and glucose metabolism, respectively. Interestingly, in the 
absence of the agonist, GSK3787 was only able to antagonize the basal expression of CPT1a. 
[42].  
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Another class of antagonists has also been identified, namely SR13904 (Figure 9). Zaveri et 
al. reported in 2009 that SR13904 inhibited cell proliferation by inhibition of the G1/S cell 
cycle, various cell cycle-related proteins and thus an increase in apoptosis. This result has, 
however, not been reproduced in studies by other research groups and thus the role of PPARδ 
antagonists as anticancer agents remains unclear [38, 42, 43].  
   
 
Figure 9. A synthetic PPARδ antagonist suggested to inhibit cell proliferation. 
 
In 2011, Müller and co-workers discovered two GSK0660-derived compounds, ST247 and 
PT-S58 (Figure 10), which exert inhibitory effects in PPARδ. These compounds proved to 
have a significantly higher affinity (IC50 = 93 nM and 98 nM) than GSK0660 (IC50 = 310 nM) 
in an in vitro TR-FRET-based competitive ligand-binding assay. ST247 was reported to 
inhibit the agonist-induced expression of PPARδ genes, in addition to actively recruit 
transcriptional corepressors and down-regulate the basal expression of PPARδ genes. In view 
of these effects, the authors classified ST247 as an inverse agonist. The recruitment of 
corepressors was not found in the case of PT-S58, indicating that this compound is a true 
antagonist [44].  
 
 
Figure 10. ST247 is reported as an inverse agonist, whereas PT-S58 is the first true antagonist. 
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In continuation, the Müller group also synthesized a series of compounds, again employing 
GSK0660 (Figure 8) as the lead compound in order to perform SAR studies. These studies 
revealed compounds 1a-1c (Figure 11) to exhibit 10-fold higher binding affinities compared 
to GSK0660 [15]. The efficacies (e. g. IC50 values) of 1a-1c have not been determined. 
 
 
Figure 11. High-affinity compounds derived from GSK0660. 
 
Recently, research by the same group revealed another inverse agonist, DG172 (IC50 = 27 
nM) to be more potent than ST247 (IC50 = 93 nM) in an in vitro TR-FRET-based competitive 
ligand-binding assay (Figure 12). DG172 is also reported to be bioavailable after oral 
application to mice [45]. The acrylonitrile moiety in this molecule has an electrophilic site, as 
in GSK3787, indicating that this Michael-acceptor can be attacked by the nucleophilic 
cysteine residue in the LDB of the PPARδ receptor. However that this reaction occurs, has yet 
to be established by LC-MS-MS, as it was in the case of GSK3787 [42]. 
 
Figure 12. The most potent PPARδ inhibitor (DG172), with the best bioavailability. 
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Antagonism versus inverse agonism 
The findings described above raise the question of whether the previously published 
antagonists in fact should be referred to as inverse agonists, given that their modes of action 
are similar to that of GSK3787, ST247 and DG172. However, given the complex nature of the 
transcriptional control exerted by PPARs and the incomplete knowledge about the mechanism 
of ligand-induced transcriptional repression, the ligands with inhibitory effects discussed in 
this thesis will consistently be referred to as antagonists.  
1.6 Identification of GSK3787 
A study of the structure-activity relationship (SAR) was carried out on a series of compounds 
focusing on the pyridyl ring, the aliphatic carbon chain and the aromatic moiety right-hand of 
the amide (Figure 13). Results from the studies suggested that an electron-withdrawing group 
such as trifluoromethyl (R1), in the para position of the pyridyl ring, was crucial for obtaining 
the activity. In addition, the thioether analogue failed to produce any activity, and it was 
therefore proposed that a sulfone group in this position was required. Furthermore, the 
molecule was only active with a two-carbon chain (n = 1) between the sulfone and the amide 
group, indicating that the length of the chain is an important factor [42]. 
However, the differences in potency resulting from substitutions on the arylamide ring were 
minor. The analogue with a 4-chloro group on the aromatic moiety (R2) was most preferable, 
even though this substitution only yielded the second highest potency compared to the 4-CF3 
group [42]. The fact that the published substitutions on the arylamide ring only resulted in 
minor changes in potency, suggests that the potency can be improved by other substitution 
patterns. 
 
 
Figure 13. Important parts for SAR studies. 
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1.7 Aim of thesis 
In this thesis, the focus was on the synthesis of more potent PPARδ-selective antagonists, 
which hopefully can be used as tools for investigating the biological effects of PPARδ 
antagonism. 
The aims of this project where: 
i. To synthesize a series of first-generation analogues of GSK3787, partly by a reported 
procedure. 
ii. To synthesize a second-generation analogue with the emphasis on developing a new 
and efficient approach.  
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2 Results and discussions 
2.1 Background for the first-generation analogues of GSK3787 
Shearer et al. reported that the trifluoromethyl substituent, the two-carbon chain and the 
sulfone group are all important parts of the pharmacophore for GSK3787 [42]. We wanted to 
investigate how changes in the arylamide moiety affected the antagonistic effects (Figure 14).  
 
 
Figure 14. Structure of GSK3787 and the first-generation analogues 7-16. 
 
2.2 Synthesis of first-generation analogues 7-16 
The key intermediate 6 was prepared over three steps according to a literature procedure, as 
reported by Shearer et al. (Scheme 1) [42].  
The preparation of thioether 4 was achieved by reacting the thiol 2 with the alkyl bromide 3 
through a nucleophilic substitution reaction (SN2). Oxidation of thioether 4 using Oxone™ 
afforded the sulfone 5. Removal of the Boc-group in 5 yielded the hydrochloride salt of the 
amine 6, which would serve as a key intermediate for further acylations.  
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Scheme 1. Synthesis of the key intermediate 6. 
 
The final step involved an acylation of the primary amine 6 with various acid chlorides 
(Scheme 2). In total, 10 analogues 7-16 were prepared, with yields between 42% and 94% 
(Table 1).  
 
 
Scheme 2. The final step of the synthesis of the first-generation analogues of GSK3787. 
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Table 1. Results of the first-generation analogues of GSK3787. 
Compound Substituent name and structure 
     R 
Yield of the final step 
    
7 phenyl 
       
60% 
8 4-fluorophenyl 
       
67% 
9 
 
 
iso-propyl 
        
 
42% 
10 
 
 
tert-butyl 
       
53% 
11 
 
 
 
2-naphthyl 
       
48% 
 
 
 12 
 
 
1-adamantyl 
       
94% 
13 
 
 
2-furyl 
       
83% 
14 
 
 
4-methoxyphenyl 
      
82% 
15 
 
 
3-pyridyl 
      
69% 
16 phenoxymethyl 
      
73% 
F
O
O
N
O
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2.3 Attempted synthesis of first-generation analogues 
In an attempt to access our target molecules 7-16 by a different synthetic route, we decided to 
start from 3-aminopropanoic acid (17). The first step of this approach involved the acylation 
of the amine, with various acid chlorides, followed by a Barton radical decarboxylation (see 
Scheme 3 for the attempted synthesis of analogue 14) [46, 47]. This reaction sequence was 
early found to be troublesome due to the poor solubility of 3-aminopropanoic acid and its 
derivatives in organic solvents, such as DMF, THF and acetone, which made the reactions 
difficult to monitor and to control. Therefore, all reactions were carried out without 
performing TLC. The intermediate alkyl bromide 20 was not detected in the 1H NMR 
spectrum of the crude reaction mixture, and it could not be established which step that had 
failed. This approach was therefore abandoned.  
 
 
Scheme 3. Attempted synthesis of the first-generation analogue 14. 
 
 
HO NH2
O
HO N
H
O O
O
THF, 66 °C
Pyridine SOCl2
CH2Cl2
Cl N
H
O O
O
O
O
Cl
17
Br
N
H
O
O
2-mercaptopyridine 
N-oxide sodium salt
AlBN 
CBrCl3 toluene
DMF
N
SH
F3C
N
H
O
O
S
N
F3C
Oxone™
Acetone:H2O / 4:1
N
H
O
O
S
N
F3C
O O
14
18 19
20
21
Et3N
 
 
21 
2.4 A second-generation analogue of GSK3787 
By serendipity, an N-methylated analogue of GSK3787 was included in a molecular 
modelling study by our collaborators. This analogue was predicted to be more potent than 
GSK3787. Hence, the focus was later directed towards the synthesis of a second-generation of 
analogues of GSK3787. Therefore compound 23 (Figure 15) was prepared, in order to gain 
more information about the potency of N-methylated analogues of GSK3787.  The 4-
fluorophenyl group was chosen because of its similarities to GSK3787. 
 
 
Figure 15. The second-generation analogue 23. 
 
In total, seven approaches towards the second-generation analogue 23 were attempted, where 
four of these possible strategies use the secondary amine 22 as a key intermediate (Figure 16), 
as it can be acylated with 4-fluorobenzoyl chloride (41) to afford the target molecule 23.  
 
 
Figure 16. The starting material 2, the key intermediate 22 and the target molecule 23. 
 
The four approaches towards the key intermediate 22, and thus the second-generation 
analogue 23, started with a nucleophilic substitution reaction (SN2) between the thiol 2 and 
various commercially available alkyl bromides. An outline of the four approaches towards 
compound 22 is shown in Figure 17.  
 
N
F3C
S
N
O
F
O O
N
SH
F3C
N
S
F3C
N
O
O
N
S
F3C
N
H
O
2
O O
22 23
F
 
 
22 
 
Figure 17. An outline of four approaches towards the key intermediate 22. 
 
In continuation, three approaches towards the second-generation analogue 23, that did not 
include key intermediate 22, were also attempted. The fifth approach was a direct N-
alkylation of compound 8, a prepared first-generation analogue, whereas the sixth approach 
differed from previously mentioned approaches, by using 4-fluorobenzoyl chloride (41) in the 
first step of the synthesis. The last approach was similar to the synthesis of the first-generation 
analogues, by using the same starting materials. All seven approaches will be described and 
discussed in more detail below (in section 2.5-2.6). 
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2.5 Attempted syntheses of N-methyl analogue 23 
2.5.1 The first approach  
The thiol 2 was treated with 1,2-dibromoethane (24) in DMF (Scheme 4). This failed to give 
us the desired product, and instead we obtained the disubstituted product 25, even though 1,2-
dibromoethane (24) was added slowly (over 1.5 hours) to the thiolate. The structure of the 
disubstituted product 25 was confirmed by both 1H and 13C NMR spectra. The NMR spectra 
are shown in the appendix.    
 
 
Scheme 4. An overview of the first approach towards 23. 
 
2.5.2 The second approach 
In this approach, we intended to use an acetal as a protecting group to avoid the problem with 
dialkylation of 1,2-bromoethane (24), as in the first approach. The thiol 2 was treated with 
bromide 28 to afford thioether 29, followed by the oxidation with Oxone™ in a 4:1 mixture of 
acetone and water, to yield sulfone 30 (Scheme 5).  
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Scheme 5. The two first steps of the second approach towards 23. 
 
Deprotection of the acetal in 30 in order to reveal the aldehyde was first attempted with 
formic acid and water in 1,4-dioxane at 60 °C (Scheme 6). However, the 1H NMR spectrum 
showed no conversion of the starting material. Therefore, a new strategy with p-
toluenesulfonic acid in acetone/water was attempted. This gave a complex mixture of 
products. Given the problems in obtaining the desired aldehyde, this approach was 
abandoned. 
 
 
Scheme 6. Attempted deprotection of the acetal 30 and the intended final steps towards 23. 
 
The intended steps after preparing the aldehyde 31 were reductive amination with 
methylamine hydrochloride in the presence of sodium cyanoborohydride to yield secondary 
amine 22, followed by acylation to afford 23. 1H, 13C and DEPT135 NMR spectra for 
compound 30 are shown in the appendix. 
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2.5.3 The third approach  
In an alternative approach, the aldehyde 34 could be accessed through oxidation of the 
alcohol 33 (Scheme 7). The thiol 2 was thus alkylated with bromoethanol 32 to give the 
alcohol 33 in 82% yield. The alcohol 33 was oxidized using DMP to yield the aldehyde 34 in 
a low yield (25%). Reductive amination on 34 was attempted, but the reaction was not 
successful, maybe due to the instability of the aldehyde. The 1H NMR spectrum did not show 
the desired product, and the approach was thus abandoned. 
 
 
Scheme 7. An overview of the third approach towards 23. 
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2.5.4 The fourth approach 
This approach avoided the problem of working with an aldehyde on the main skeleton by 
performing a reductive amination using paraformaldehyde and the primary amine 38 (Scheme 
8). To reach the primary amine 38, the thiol 2 was alkylated with bromoacetonitrile (36) to 
give the nitrile 37, followed by reduction to yield the primary amine 38. The reduction of the 
nitrile failed, perhaps due to an interaction between the pyridine and the aluminium in 
LiAlH4. During the reaction, the mixture turned from colourless to blue, indicating this 
possible complex. The use of a milder reducing agent was not investigated.  
 
 
Scheme 8. An overview of the fourth approach towards 23. 
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2.5.5 The fifth approach: a direct N-alkylation  
Starting with a secondary amide and thereby avoiding overalkylation [48], a direct N-
alkylation was suggested to be a short route to 23. A direct N-alkylation of the prepared first-
generation analogue 8 was attempted, using NaHMDS as a base, with a large excess of MeI in 
THF (Scheme 9). The reaction did not provide the desired product. However, this result could 
have been caused by the difficulty of using the volatile MeI on a small scale. The acidic α-
protons of the sulfone may also contribute to potential problems in this reaction, giving the α-
alkylated product instead of the desired N-methylation. 
 
 
Scheme 9. An attempted direct N-alkylation of compound 8 to yield 23. 
 
2.5.6 The sixth approach 
This approach employed the commercially available N-methyl aminoethanol (40) as a starting 
material (Scheme 10). The double N,O-acylation afforded the amidoester 42, in which the 
benzoic ester could be selectively hydrolysed in a subsequent step, yielding the alcohol 43. In 
this fashion the N-methylated arylamide moiety could be obtained in a reliable acylation 
reaction, in excellent yields (91%). 
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Scheme 10. An overview of the sixth approach towards 23. 
 
The benzoic ester was hydrolysed using K2CO3 in MeOH, to afford the alcohol 43 in a low 
yield. Attempts were made to improve the yield by increasing the reaction time. Monitoring 
the reaction with TLC confirmed full conversion of starting material 42, but it was still 
difficult to obtain a high yield of 43 after purification. Due to the low yields (between 22% 
and 45%), this reaction was also attempted with LiOH in a 4:1 mixture of THF and water, but 
these conditions failed to improve the yield. The bromination of alcohol 43 to afford bromide 
45 was attempted by three different strategies. All reactions were unsuccessful, even though 
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this approach seemed very promising on paper. In a final attempt, a substitution reaction 
between the thiol 2 and the mesylate 44 was hampered by the failure to obtain the mesylate 44 
from the alcohol 43 and mesyl chloride. On the basis of the described difficulties, the 
abovementioned strategies were also abandoned. 1H, 13C and DEPT135 NMR spectra of the 
amidoester 42, as well as a 1H NMR spectrum of alcohol 43, are shown in the appendix. The 
experimental procedures for these compounds (42 and 43) are listed in section 5.4.  
 
2.6 Successful synthesis of the N-methyl analogue 23 
The synthetic approach, which afforded compound 23 (Scheme 11), included five steps.  
The synthesis started similarly to the abovementioned approaches, with a nucleophilic 
substitution reaction (SN2) to yield the thioether 4. Instead of oxidizing thioether 4 to the 
sulfone group with acidic α-protons, the compound was directly N-deprotected using HCl in 
dioxane to yield the amine hydrochloride salt 47. The following acylation with the acid 
chloride 41 was performed in the same manner as earlier, to give the amide 48. The yield over 
the three steps was 66%.   
The N-methylated compound 49 was achieved by using a great excess of MeI as the 
methylation reagent in THF in the presence of NaH. The following oxidation of the thioether 
group, yielded sulfone 23. When monitoring the reaction, the N-methyl amide 49 was 
expected to be more lipophilic than its N-H analogue 48. However, this was not the case, and 
could be explained by an intramolecular hydrogen bond between the nitrogen atom in the 
pyridine ring and the amide N-H, which would make thioether 48 more lipophilic than 49, due 
to the masking of its polar groups. In sum, this approach was successful and provided the 
desired product. Due to time constraints, only one analogue of the second generation was 
prepared.  
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Scheme 11. The successful synthesis of the second-generation analogue 23. 
 
2.7 Alternative synthesis of compound 23 
In a paper published by Ishibashi and colleagues, a nucleophilic substitution reaction between 
an arylthiolate and N-methyl-2-oxazolidinone (50) in PrOH was able to afford the secondary 
ethylamine in 98% yield. It was reported to be a reaction completed within 30 minutes [49]. 
The same approach was therefore suggested for the thiol 2 and the methyl oxazolidinone 50 to 
yield the secondary amine 35 (Scheme 12). An acylation of the secondary amine 35, followed 
by oxidation with Oxone™ could yield the target molecule 23. This approach was not 
explored due to the fact that a successful approach was already achieved.  
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Scheme 12. An alternative synthesis of compound 23, using thiol 2 and methyl oxazolidinone 50 as starting 
materials.  
 
2.8      Molecular modelling 
Molecular modelling studies were performed by Ph.D. student Åsmund Kaupang. The 
prepared compounds 7-16 and 23 were docked into the LBD of PPARδ. The findings from 
these studies showed that compound 23 of the synthesized analogues (Figure 18 and 19) has 
the highest docking score, followed by compound 11 (Figure 18 and 20). The docking score 
indicates that the compounds exhibit favourable interactions within the PPARδ LBD, and thus 
that they should have affinity for the binding pocket. Compound 8, which is the N-H analogue 
of 23, scored significantly lower in the docking studies. Since the N-methyl substitution was 
beneficial for the binding properties, an N-methyl analogue of 11 was also submitted to 
docking. This compound displayed even better binding properties than both 11 and 23. 
Currently, further molecular modelling studies are ongoing aiming at generating new lead 
compounds as selective PPARδ antagonists.       
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Figure 18. The two prepared compounds 23 and 11 displayed the best binding properties in the molecular 
modelling studies. 
 
 
 
Figure 19. Molecular modeling of compound 23 in the PPARδ LBD. 
 
 
Figure 20. Molecular modelling of compound 11 in the PPARδ LBD. 
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3 Conclusion and future work  
Synthesis 
The synthetic efforts resulted in eleven putative antagonists of PPARδ. The first-generation 
analogues 7-16 were synthesized in part by a known synthetic method, followed by an 
acylation reaction. An efficient approach for the second-generation analogues was developed, 
which afforded compound 23. This method may prove useful for the synthesis of additional 
analogues suitable for SAR studies. 
 
Biological studies 
The biological studies of compounds 7-16 and 23 are currently ongoing. The in vitro testing 
will reveal the potency of the prepared analogues, and an initial structure activity relationship 
can be established when the biological results are available. 
 
Molecular modelling  
Molecular modelling studies were performed and indicate that the second-generation 
compound 23 outperform the first-generation compounds. Since compound 11 showed to 
have the best binding properties among the first-generation analogues, an N-methyl analogue 
of 11 was also submitted to docking. This compound displayed even better binding properties 
than both 11 and 23. This finding suggests that the N-methyl analogue of 11 should be 
synthesized and biologically evaluated.  
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4 Spectroscopic elucidation and characterization of 
compounds 
 
4.1 General characterization of intermediates and analogues  
The prepared analogues and intermediates 4-16, 23 and 37-39 share a common moiety, and 
will therefore be discussed in general (Figure 21).  
 
 
Figure 21. General structure of prepared analogues and their intermediates. The numerations are not in 
accordance with the IUPAC rules.   
 
The recorded 1H NMR spectra show characteristic signals for aromatic protons, which 
typically occur between 6 ppm and 8 ppm. The proton with the highest chemical shift value, 
furthest downfield, is likely to be the proton in position 6 (Figure 21). This is explained by the 
deshielding effect of the electronegative trifluoromethyl group and the nitrogen atom in the 
pyridine ring. According to the literature, the coupling constants in a benzene ring system are 
J = 7.5 Hz for ortho coupling, J = 1.5 Hz for meta coupling and J = 0.7 Hz for para coupling 
[50]. These coupling constants will be used as guidelines in the structure elucidation of the 
prepared compounds. The aromatic protons in position 3 and 4 will occur as a double doublet 
and a doublet, with an ortho and a meta coupling, and an ortho coupling, respectively. The 
protons (in position 7 and 8) in the alkyl chain typically appear at 3-4 ppm, due to the lower 
electron density around them, caused by the electron withdrawing sulfone and amide group. 
The proton in position 9 occurs as a triplet, typically at 6-8 ppm. However, the chemical shift 
values for the N-H protons vary with different solvents and concentrations.  
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The 13C NMR spectra obtained for all compounds show two important and characteristic 
signals at 120-130 ppm. Each of these two signals is split into a quartet, explained by the 
three fluorine atoms coupled to the carbon in position 1. These quartets are therefore assigned 
to the carbons in position 1 and 2. However, the quartet assigned to the carbon in position 2 
has a lower coupling constant and a higher chemical shift value, caused by the electron 
withdrawing sulfone group.  
Typically, the most downfield signals are assigned to the carbon atoms in position 10 and 5, 
where the carbonyl in position 10 has the highest chemical shift value. The carbon in position 
6 generally appears more downfield compared to the carbon in position 3 and 4, which is due 
to the electron withdrawing effects of the trifluoromethyl group and the nitrogen atom in the 
pyridine ring. As expected from the literature, the carbons in the alkyl chain  (in position 7 
and 8) are detected as the most upfield signals.  
All compounds, except 4-6, have to the best of our knowledge not previously been reported or 
characterized in the literature.  
 
4.2 Spectroscopic characterization of first-generation analogues 7-16 and 
their intermediates 4-6 
4.2.1 Characterization of compound 4  
Compound 4 has already been characterized in the literature by Shearer and co-workers and 
the obtained 1H NMR spectrum is in accordance with the published data [42]. However, this 
compound does not apply to the general rule discussed in section 4.1, owing to the fact that 
the thioether group is less electron withdrawing than the sulfone group. Therefore, the 
quarternary carbon at position 1 has a higher chemical shift value than the carbon at position 
2. The 1H NMR and 13C NMR chemical shifts are assigned to the numbered positions in 
Figure 22 and Table 2. The 1H and 13C NMR spectra are shown in the appendix. 
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Figure 22. Atom numbering of compound 4. 
 
 
Table 2. Assignment of chemical shift values for compound 4. 
 
 
 
4.2.2 Characterization of compound 5  
Compound 5 has already been characterized in the literature by Shearer and co-workers and 
the obtained 1H NMR spectrum is in accordance with the published data [42]. The 1H NMR 
and 13C NMR chemical shifts are assigned to the numbered positions in Figure 23 and Table 
3. The 1H and 13C NMR spectra are shown in the appendix. 
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1 - - - 123.93 q 271.7
2 - - - 121.01 q 32.6
3 7.97 dd 8.6, 2.5 133.33 d 3.2
4 7.53 d 8.5 121.73 - -
5 - - - 163.95 - -
6 8.77 s - 145.90 - -
7 3.32 – 3.13 m - 39.42 - -
8 3.32 – 3.13 m - 29.30 - -
9 7.05 m - - - -
10 - - - 155.53 - -
11 - - - 77.73 - -
12 1.37 d 4.8 28.17 - -
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Figure 23. Atom numbering of compound 5. 
 
 
Table 3. Assignment of chemical shift values for compound 5. 
 
 
4.2.3 Characterization of compound 6  
Shearer and co-workers have earlier performed the 1H NMR characterization of compound 6 
[42]. The obtained 1H NMR spectrum is roughly in accordance with the published data, 
except for the broad singlet, which is shifted upfield from 8.11 ppm to 8.48 ppm. Given that 
both spectra are recorded in DMSO-d6, this inconsistency may be caused by a difference in 
concentration of the NMR sample. The 1H NMR and 13C NMR chemical shifts are assigned to 
the numbered positions in Figure 24 and Table 4. The 1H, 13C and DEPT135 NMR spectra are 
shown in the appendix.  
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4
3
2
6
N
F3C1
S
7
8
N
H
9
10
O
11
12
O 12
12O O
Position !H Multiplicity Coupling constant        
(J Hz)
!C Multiplicity Coupling constant  
(J Hz)
1 - - - 122.85 q 273.3
2 - - - 128.38 q 32.9
3 8.62 dd - 137.03 d 3.5
4 8.25 d 8.2 122.29 - -
5 - - - 160.09 - -
6 9.23 s - 148.84  – 146.23 m -
7 3.68 t 6.4 50.90 - -
8 3.31 q 5.9 34.33 - -
9 6.79 t 5.2 - - -
10 - - - 155.06 - -
11 - - - 78.00 - -
12 1.27 s - 27.99 - -
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Figure 24. Atom numbering of compound 6. 
 
 
Table 4. Assignment of chemical shift values to compound 6. 
 
 
4.2.4 Characterization of compound 7  
The chemical shift values for the atoms at position 1-8 share the same characteristics as 
described in section 4.1, except the protons in position 3 and 4, which occur as multiplets. The 
five protons in the arylamide moiety appear between 7.26 ppm and 7.66 ppm, as expected for 
aromatic protons. The 1H NMR and 13C NMR chemical shifts are assigned to the numbered 
positions in Figure 25 and Table 5. The 1H, 13C and DEPT135 NMR spectra are shown in the 
appendix. 
 
 
 
3
2
6
N
5
4
F3C1
S
7
8
NH3+Cl- 9
O O
Position !H Multiplicity Coupling constant     
(J Hz)
!C Multiplicity Coupling constant   
(J Hz)
1 - - - 122.75 q 273.4
2 - - - 128.85 q 33.1
3 8.76 – 8.56 m - 137.42 q 3.4
4 8.31 d 8.2 122.48 - -
5 - - - 159.16 - -
6 9.27 s - 147.57 q 3.6
7 4.07 – 3.81 m - 49.04 - -
8 3.32 – 3.06 m - 32.85 - -
9 8.48 bs - - - -
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Figure 25. Atom numbering of compound 7. 
 
 
Table 5. Assignment of chemical shift values to compound 7. 
 
 
4.2.5 Characterization of compound 8  
The 1H and 13C NMR chemical shifts are assigned to the numbered positions in Figure 26 and 
Table 6. The 13C NMR spectra display a double doublet and a multiplet for the carbons in 
position 12 and 13, respectively, due to the substituted aromatic fluorine atom. The 1H, 13C 
and DEPT135 NMR spectra are shown in the appendix. 
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4
3
2
6
N
F3C1
S
7
8
N
H
9
O O
10
O
11
12
13
14
13
12
Position !H Multiplicity Coupling constant     
(J Hz)
!C Multiplicity Coupling constant   
(J Hz)
1 - - - 122.63 q 273.2
2 - - - 128.23 q 33.00
3 8.60 – 8.39 m - 136.86 q 3.4
4 8.60 – 8.39 m - 122.18 - -
5 - - 160.01 - -
6 9.08 s - 147.20 q 3.8
7 3.89 t 6.2 50.34 - -
8 3.66 q 6.0 33.76 - -
9 8.24 m - - - -
10 - - - 165.94 - -
11 - - - 133.29
12 7.66 – 7.26 m - 126.83 - -
13 7.66 – 7.26 m - 128.09 - -
14 7.66 – 7.26 m - 131.32 - -
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Figure 26. Atom numbering of compound 8. 
 
 
Table 6. Assignment of chemical shift values to compound 8. 
 
 
4.2.6 Characterization of compound 9  
The 1H and 13C NMR chemical shifts are assigned to the numbered positions in Figure 27 and 
Table 7. The CH3-groups in position 12 appear at 0.85 ppm, as expected for aliphatic protons. 
The proton in position 11 occurs as a heptet at 2.07 ppm, which is in accordance with the 
literature value. The 1H, 13C and DEPT135 NMR spectra are shown in the appendix. 
 
 
 
 
5
4
3
2
6
N
F3C1
S
7
8
N
H
9
10
O
11
12
13
14
13
12
F
O O
Position !H Multiplicity Coupling constant(s)     
(J Hz)
!C Multiplicity Coupling constant   
(J Hz)
1 - - - 122.61 q 273.2
2 - - - 128.15 q 32.9
3 7.75 – 7.58 m - 136.85 q 3.4
4 7.75 – 7.58 m - 122.13 - -
5 - - - 160.05 d 160.9
6 9.12 – 8.95 m - 147.17 q 3.8
7 3.89 t 6.1 50.22 - -
8 3.64 m - 33.87 - -
9 8.22 m - - - -
10 - - - 164.78 - -
11 - - - 129.67 d 2.9
12 8.47 dd 8.0, 2.3 129.49 d 9.1
13 7.32 – 7.10 m - 115.03 d 21.8
14 - - - 163.95 d 248.8
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Figure 27. Atom numbering of compound 9. 
 
 
Table 7. Assignment of chemical shift values to compound 9. 
 
 
4.2.7 Characterization of compound 10  
The 1H NMR and 13C NMR chemical shifts are assigned to the numbered positions in Figure 
28 and Table 8. The observed doublet at 0.85 ppm, which integrates for nine protons, 
indicates the three CH3-groups in position 12. The 1H, 13C and DEPT135 NMR spectra are 
shown in the appendix. 
 
 
 
5
4
3
2
6
N
F3C1
S
7
8
N
H
9
10 11
12
O
12
O O
Position !H Multiplicity Coupling constant(s)   
(J Hz)
!C Multiplicity Coupling constant   
(J Hz)
1 - - - 122.82 q 273.3
2 - - - 128.48 q 33.0
3 8.62 dd 8.4, 1.7 137.08 - -
4 8.26 d 8.2 122.28 - -
5 - - - 160.01 - -
6 9.24 s - 147.39 - -
7 3.69 t 6.5 50.66 - -
8 3.41 q 6.3 32.83 - -
9 7.83 t 5.7 - - -
10 - - - 176.20 - -
11 2.07 h 6.9 33.69 - -
12 0.85 d 6.9 19.17 - -
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Figure 28. Atom numbering of compound 10. 
 
 
Table 8. Assignment of chemical shift values to compound 10. 
 
 
4.2.8 Characterization of compound 11 
Most of the 1H and 13C NMR chemical shifts are assigned to the numbered positions in Figure 
29 and Table 9. However, the chemical shift values for the naphthalene ring are difficult to 
assign. Instead, a range of chemical shifts is assigned to the aromatic protons and carbons, 
except position 6. The 1H, 13C and DEPT135 spectra are shown in the appendix. 
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F3C1
S
7
8
N
H
9
O O
10
O
11
12
12
12
Position !H Multiplicity Coupling constant(s)   
(J Hz)
!C Multiplicity Coupling constant   
(J Hz)
1 - - - 122.81 q 273.2
2 - - - 128.51 q 33.0
3 8.62 dd 8.5, 1.9 137.10 q 3.6
4 8.26 d 8.2 122.30 - -
5 - - - 159.95 - -
6 9.25 s - 147.42 q 3.8
7 3.70 t 6.6 50.63 - -
8 3.42 q 6.5 33.16 - -
9 7.55 t 5.4 - - -
10 - - - 177.61 - -
11 - - - 33.16 - -
12 0.93 s - 27.06 - -
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Figure 29. Atom numbering of compound 11. 
 
 
Table 9. Assignment of chemical shift values to compound 11. 
 
 
4.2.9 Characterization of compound 12  
The 1H and 13C NMR chemical shifts are assigned the numbered positions in Figure 30 and 
Table 10. The 1H, 13C and DEPT135 NMR spectra are shown in the appendix. 
 
 
5
4
3
2
6
N
F3C1
S
7
8
N
H
9
O O
10
O
11
20
19
18
13
12
17
16
15
14
Position !H Multiplicity
Coupling constant     
(J Hz) !C Multiplicity
Coupling constant   
(J Hz)
1 - - - 122.50 q 273.4
2 - - - 128.19 q 33.1
3 * - - 136.84 q 3.4
4 * - - 122.18 - -
5 - - - 160.29 – 159.58 m -
6 9.05 - - 147.19 q 3.8
7 3.94 t 6.0 50.38 - -
8 3.72 q 5.6 33.88 - -
9 8.66 t 4.8 - - -
10 - - - 165.98 - -
11 - - - 131.92 - -
12 8.46 - - 128.75 - -
13 - - - 134.17 - -
14 * - - ** - -
15 * - - ** - -
16 * - - ** - -
17 * - - ** - -
18 - - - 130.63 - -
19 * - - ** - -
20 * - - ** - -
* the chemical shift value for this proton is in the range of 7.52 - 8.27 ppm. 
** the chemical shift value for this carbon is in the range of 123.61 - 127.74 ppm.
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Figure 30. Atom numbering of compound 12. 
 
 
Table 10. Assignment of chemical shift values to compound 12. 
 
 
4.2.10 Characterization of compound 13  
The 1H NMR and 13C NMR chemical shifts are assigned to the numbered positions in Figure 
31 and Table 11. The 1H, 13C NMR and DEPT135 NMR spectra are shown in the appendix. 
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F3C1
S
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N
H
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O O
10
O
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12
14
13
14
12
13
12
13
14
Position !H Multiplicity
Coupling constant     
(J Hz) !C Multiplicity
Coupling constant   
(J Hz)
1 - - - 122.51 q 273.4
2 - - - 130.41 q 33.9
3 8.25 s - 136.16 q 3.3
4 8.25 s - 121.93 - -
5 - - - 160.48 - -
6 9.00 s - 147.44 q 3.8
7 3.71 – 3.59 m - 51.90 - -
8 3.79 q 5.8 33.12 - -
9 6.42 t - - - -
10 - - - 178.36 - -
11 - - - 40.69 - -
12 1.80 s - 39.13 - -
13 1.77 – 1.62 m - 36.54 - -
14 2.02 s - 28.13 - -
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Figure 31. Atom numbering of compound 13. 
 
 
Table 11. Assignment of chemical shift values to compound 13. 
 
 
4.2.11 Characterization of compound 14  
The 1H NMR and 13C NMR chemical shifts are assigned to the numbered positions in Figure 
32 and Table 12. The four protons in position 12 and 13 occur as doublets, and the coupling 
constants indicate both positions to be ortho coupled with the vicinal protons. The signal at 
3.78 ppm integrates for three protons, and is assigned to position 15, typical for O-methyl. 
The 1H and 13C NMR spectra are shown in the appendix. 
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F3C1
S
7
8
N
H
9
O O
10
11
O
O
14
13
12
Position !H Multiplicity Coupling constant     
(J Hz)
!C Multiplicity Coupling constant   
(J Hz)
1 - - - 122.48 q 273.5
2 - - - 130.30 q 33.8
3 7.41 s - 136.04 q 3.4
4 8.45 – 8.01 m - 121.89 - -
5 - - - 158.33 - -
6 8.92 s - 147.48 – 147.17 m -
7 4.01 – 3.92 m - 51.93 - -
8 3.84 – 3.71 m - 33.29 - -
9 6.95 t - - - -
10 - - - 160.61 - -
11 - - - 158.33 - -
12 7.05 d 3.4 114.89 - -
13 6.60 – 6.41 m - 112.38 - -
14 8.45 – 8.01 m - 144.3 - -
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Figure 32. Atom numbering of compound 14. 
 
 
Table 12. Assignment of chemical shift values to compound 14. 
 
 
4.2.12 Characterization of compound 15  
The 1H NMR and 13C NMR chemical shifts are assigned to the numbered positions in Figure 
33 and Table 13. The 1H, 13C, DEPT135 and COSY45 NMR spectra are shown in the 
appendix. 
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F3C1
S
7
8
N
H
9
O O
10
O
11
12
13
14
13
12
O
15
Position !H Multiplicity Coupling constant(s)   
(J Hz)
!C Multiplicity Coupling constant   
(J Hz)
1 - - - 122.63 q 273.3
2 - - - 128.13 q 33.0
3 8.46 dd 8.3. 1.8 136.81 q 3.3
4 8.22 d 8.2 122.10 - -
5 - - - 160.03 - -
6 9.04 s - 147.14 q 3.7
7 3.87 t 6.2 55.26 - -
8 3.62 q 6.0 33.73 - -
9 8.29 t 5.3 - - -
10 - - - 165.38 - -
11 - - - 125.47 - -
12 7.55 d 8.9 128.66 - -
13 6.89 d 8.9 113.27
14 - - - 161.66 - -
15 3.78 s - 50.39 - -
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Figure 33. Atom numbering of compound 15. 
 
 
Table 13. Assignment of chemical shift values to compound 15. 
 
 
4.2.13 Characterization of compound 16  
The 1H NMR and 13C NMR chemical shifts are assigned to the numbered positions in Figure 
34 and Table 14. The signal assigned to the protons at position 11 display as a singlet. The 
chemical shift values for the five aromatic protons in position 13-15 are in accordance with 
the shift range for aromatic protons.  The 1H, 13C NMR and DEPT135 NMR spectra are 
shown in the appendix. 
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N
F3C1
S
7
8
N
H
9
O O
10 11
O
15
N
14
13
12
Position !H Multiplicity Coupling constant(s)  
(J Hz)
!C Multiplicity Coupling constant   (J 
Hz)
1 - - - 122.58 q 273.4
2 - - - 128.23 q 33.1
3 8.25 d 8.2 136.89 q 3.3
4 8.55 – 8.45 m - 122.18 - -
5 - - - 160.02 - -
6 8.80 – 8.73 m - 148.00 - -
7 3.90 t 6.2 50.16 - -
8 3.67 q 5.9 33.76 - -
9 8.73 – 8.62 m - - - -
10 - - - 164.52 - -
11 - - - 128.70 - -
12 7.94 m - 134.53 - -
13 7.42 m - 123.23 - -
14 8.73 – 8.62 m - 147.20 q 3.6
15 9.08 - - 151.98 - -
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Figure 34. Atom numbering of compound 16. 
 
 
Table 14. Assignment of chemical shift values to compound 16. 
 
 
4.3 Spectroscopic characterization of the second-generation analogue 23 
and its intermediates 48-49 
4.3.1 Characterization of compound 48  
The 1H NMR chemical shifts are assigned to the numbered positions in Figure 35 and Table 
15. The proton in position 9 occurs as a broad singlet, which can be explained by the low 
concentration of the NMR sample. The 1H NMR spectrum is shown in the appendix. 
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N
H
9
O O
10
O
11
O
12
13
14
15
14
13
Position !H Multiplicity Coupling constant(s)   
(J Hz)
!C Multiplicity Coupling constant   (J 
Hz)
1 - - - 122.73 q 273.3
2 - - - 128.49 q 33.1
3 8.57 dd 8.2. 1.8 137.06 q 3.5
4 8.26 d 8.2 122.32 - -
5 - - - 157.37 - -
6 9.22 s - 147.36 q 3.8
7 3.77 t 6.6 50.48 - -
8 3.54 q 6.4 32.58 - -
9 8.14 t 5.6 - - -
10 - - - 167.75 - -
11 4.28 s - 66.61 - -
12 - - - 159.85 - -
13 7.28 dd 8.6. 7.4 114.65 - -
14 7.05 – 6.81 m - 129.45 - -
15 7.05 – 6.81 m - 121.27 - -
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Figure 35. Atom numbering of compound 48. 
 
 
Table 15. Assignment of 1H NMR chemical shift values to compound 48. 
 
 
4.3.2 Characterization of compound 49  
The 1H NMR chemical shifts are assigned to the numbered positions in Figure 36 and Table 
16. The singlet at 3.08 ppm is in accordance with a typical chemical shift of an N-methyl 
group. The signals at 6.34-7.96 ppm are assigned to the four aromatic protons in the 4-
fluorophenyl moiety. The 1H NMR spectrum is shown in the appendix. 
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N
S
F3C1
7
8
N
H
9
10
O
11
12
13
14
13
12
F
Position !H Multiplicity 
Coupling constant     
(J Hz)
1 - - -
2 - - -
3 7.95 – 7.60 m -
4 7.34 d 8.3
5 - - -
6 8.63 s -
7 3.49 t 6.1
8 3.79 q 6.5
9 7.23 bs -
10 - - -
11 - - -
12 7.95 – 7.60 - -
13 7.06 m -
14 - - -
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Figure 36. Atom numbering of compound 49. 
 
 
Table 16. Assignment of 1H NMR chemical shift values to compound 49. 
 
 
4.3.3 Characterization of compound 23  
The 1H NMR and 13C NMR chemical shifts are assigned to the numbered positions in Figure 
37 and Table 17. The characteristic splitting patterns (doublets) caused by the substituted 
fluorine atom in the 4-fluorophenyl moiety are visible in the 13C NMR spectra. The 1H, 13C 
and DEPT135 NMR spectra are shown in the appendix.  
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O
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12
13
14
13
12
F
9
Position !H Multiplicity  
Coupling constant       
(J Hz)
1 - - -
2 - - -
3 7.96 – 6.34 m -
4 7.96 – 6.34 m -
5 - - -
6 8.53 d 115.9
7 4.31 – 3.16 m -
8 4.31 – 3.16 m -
9 3.08 s -
10 - - -
11 - - -
12 7.96 – 6.34 m -
13 7.96 – 6.34 m -
14 - - -
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Figure 37. Atom numbering of compound 23. 
 
 
Table 17. Assignment of chemical shift values to compound 23. 
 
 
4.4 Spectroscopic characterization of compounds from attempted 
approaches  
4.4.1 Characterization of intermediates from the sixth approach 
Characterization of compound 42 
The 1H NMR and 13C NMR chemical shifts are assigned to the numbered positions in Figure 
38 and Table 18. The 1H and 13C NMR spectra are shown in the appendix. 
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Position !H Multiplicity Coupling constant       (J Hz) !C Multiplicity Coupling constant   (J Hz)
1 - - - 122.53 q 273.5
2 - - - 130.34 q 34.0
3 7.50 – 7.34 m - 136.84 – 135.36 m -
4 7.50 – 7.34 m - 121.96 - -
5 - - - 160.46 - -
6 8.99 s - 147.91 – 146.71 m -
7 3.92 d 51.1 49.34 - -
8 3.92 d 51.1 42.46 - -
9 3.09 s - 39.05 - -
10 - - - 171.01 - -
11 - - - 131.63 d 3.5
12 8.24 s - 129.49 d 6.8
13 7.08 m - 115.66 d 21.9
14 - - - 163.63 d 250.6
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Figure 38. Atom numbering of compound 42. 
 
 
Table 18. Assignment of chemical shift values to compound 42. 
 
 
 
Characterization of compound 43 
The 1H NMR chemical shifts are assigned to the numbered positions in Figure 39 and Table 
19. The 1H NMR spectrum is shown in the appendix. 
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2
1
2
3
F
O
8
Position !H Multiplicity Coupling constant(s)   
(J Hz)
!C Multiplicity Coupling constant(s)   
(J Hz)
1 - - - 156.06 - -
2 7.20 – 6.96 m - 115.71 dd 21.9, 12.9
3 7.39 dd 8.4. 5.3 132.31 d 9.5
4 - - - 126.10 - -
5 - - - 164.33 - -
6 4.88 – 4.28 m - 62.22 - -
7 4.09 – 3.63 m - 46.94 - -
8 3.11 - - 38.99 - -
9 - - - 167.70 - -
10 - - - 132.17 d 3.5
11 8.25 – 7.87 m - 129.30 d 8.4
12 7.20 – 6.96 m - 115.71 dd 21.9, 12.9
13 - - - 161.75 - -
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Figure 39. Atom numbering of compound 43. 
 
 
Table 19. Assignment of 1H NMR chemical shift values to compound 43. 
 
HO1
2
3
N
5
4
6
O
7
8
9
8
7
F
Position !H Multiplicity 
Coupling constant       
(J Hz)
1 4.03 – 3.29 m -
2 4.03 – 3.29 m -
3 4.03 – 3.29 m -
4 3.03 s -
5 - - -
6 - - -
7 7.43 s -
8 7.06 s -
9 - - -
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5 Experimental section 
5.1 General  
Unless noted otherwise, all reagents and solvents were used as purchased without further 
purification. Thin layer chromatography (TLC) was performed using silica gel 60 F254-plates. 
Flash column chromatography was performed on silica gel 60 (40-63 µm, Fluka). Hexane was 
distilled prior to use.  
To record the NMR spectra, Bruker Advance DPX-300 MHz spectrometer or Bruker 
Advance DPX 400 Fourier Transform spectrometer were used. Coupling constants (J) are 
reported in hertz, while the chemical shift values are reported in parts per million (ppm, δ), 
relative to CDCl3 (7.26 ppm for 1H and 77.16 ppm for 13C) and DMSO-d6 (2.50 ppm for 1H 
and 39.52 ppm for 13C). Some of the spectra contain an additional singlet at 0.00 ppm 
representing TMS added to the solvent as an internal standard.  
5.2 First-generation analogues  
5.2.1 Synthesis of intermediates  
Synthesis of tert-butyl (2-((5-(trifluoromethyl)pyridin-2-yl)thio)ethyl)carbamate (4) 
To a stirred solution of 5-(trifluoromethyl)pyridine-2-thiol (2.00 g, 11.1 mmol) in DMF (40 
mL) was added Et3N (4.0 mL, 28.8 mmol), followed by a solution of 2-(N-Boc-amino)ethyl 
bromide (2.72 g, 12.1 mmol) in DMF (20 mL). The mixture was stirred for 1 hour and 
monitored with TLC. After completion of the reaction, the mixture was poured into water 
(100 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were washed 
with water (2 x 50 mL) and brine (50 mL), dried (MgSO4) and the solvent was removed under 
reduced pressure. The remaining colourless solid was obtained in 97% yield (3.46 g, 10.7 
mmol) and used without further purification. 1H NMR (300 MHz, DMSO-d6): δ 8.77 (s, 1H), 
7.97 (dd, J = 8.6, 2.5 Hz, 1H), 7.53 (d, J = 8.5 Hz, 1H), 7.05 (m, 1H), 3.32 – 3.13 (m, 4H), 
1.37 (d, J = 4.8 Hz, 9H). 13C NMR (75 MHz, DMSO-d6): δ 163.95, 155.53, 145.90, 133.33 (d, 
J = 3.2 Hz), 123.93 (q, J = 271.7 Hz), 121.73, 121.01 (q, J = 32.6 Hz), 77.73, 39.42, 29.30, 
28.17. 
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Synthesis of tert-butyl (2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethyl)carbamate (5) 
To a mixture of compound 4 (2.00 g, 6.2 mmol) in acetone and water (4:1, 10 mL) was added 
Oxone™ (15.0 g, 24.4 mmol) and the reaction was stirred overnight. Acetone was removed 
under reduced pressure and the remaining aqueous suspension was poured into water (10 mL) 
and extracted with EtOAc (20 mL). The combined organic phases were washed with brine (20 
mL), dried (MgSO4) and the solvent was removed under reduced pressure. The remaining 
solid was purified using column chromatography, which afforded 5 as a colourless solid in 
57% yield (1.25 g, 3.5 mmol). Mp 146-169 °C. Rf = 0.20 (4:6 EtOAc:hexane). 1H NMR (300 
MHz, DMSO-d6): δ 9.23 (s, 1H), 8.62 (dd, 1H), 8.25 (d, J = 8.2 Hz, 1H), 6.79 (t, J = 5.2 Hz, 
1H), 3.68 (t, J = 6.4 Hz, 2H), 3.31 (q, J = 5.9 Hz, 2H), 1.27 (s, 7H). 13C NMR (75 MHz, 
DMSO-d6): δ 160.09, 155.06, 148.84 – 146.23 (m), 137.03 (d, J = 3.5 Hz), 128.38 (q, J = 32.9 
Hz), 122.85 (q, J = 273.3 Hz), 122.29, 78.00, 50.90, 34.33, 27.99. 
 
Synthesis of 2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethanaminium chloride (6) 
To compound 5 (2.10 g, 5.9 mmol) was added HCl in dioxane (50 mL) and the reaction was 
stirred for 3 hours. The suspension was diluted with Et2O (50 mL) and stirred for 10 minutes. 
The resulting precipitate was filtered, rinsed with Et2O (20 mL) and the solid was collected. 
The residual solvent was removed under reduced pressure and the solid was dried under 
reduced pressure overnight. This afforded the colourless hydrochloride salt 6 in 91% yield 
(1.57 g, 5.4 mmol), which was used without further purification. Mp 193-195 °C. 1H NMR 
(400 MHz, DMSO-d6): δ 9.27 (s, 1H), 8.76 – 8.56 (m, 1H), 8.48 (s, 3H), 8.31 (d, J = 8.2 Hz, 
1H), 4.07 – 3.81 (m, 2H), 3.32 – 3.06 (m, 2H). 13C NMR (101 MHz, DMSO-d6): δ 159.16, 
147.57 (q, J = 3.6 Hz), 137.42 (q, J = 3.4 Hz), 128.85 (q, J = 33.1 Hz), 122.75 (q, J = 273.4 
Hz), 122.48, 49.04, 32.85. 
 
5.2.2 General procedure for the synthesis of first-generation analogues  
To a stirred solution of 2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethanaminium chloride 
(6) (0.87 mmol) in dry THF (10 mL) at 0 °C was added Et3N (0.6 mL, 4.0 mmol). To this 
solution, the acid chloride (2.0 mmol) in dry THF (4 mL) was added dropwise. The mixture 
was stirred at room temperature for 1 hour, then poured into water (50 mL) and extracted with 
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EtOAc (3 x 20 mL). The combined organic phases were washed with saturated aqueous 
NH4Cl (3 x 20 mL), water (20 mL), brine (20 mL), dried (MgSO4) and evaporated under 
reduced pressure. The crude products were purified using column chromatography on silica 
gel and dried under reduced pressure overnight.  
 
Synthesis of N-(2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethyl)benzamide (7) 
The title compound was obtained as a colourless solid in 60% yield (185 mg, 0.5 mmol) from 
6 (254 mg, 0.87 mmol) and benzoyl chloride (324 mg, 2.0 mmol) according to the general 
procedure. Mp 156-158 °C. Rf = 0.09 (1:99 MeOH:CH2Cl2). 1H NMR (300 MHz, DMSO-d6): 
δ 9.08 (s, 1H), 8.60 – 8.39 (m, 2H), 8.24 (m, 1H), 7.66 – 7.26 (m, 5H), 3.89 (t, J = 6.2 Hz, 
2H), 3.66 (q, J = 6.0 Hz, 2H). 13C NMR (75 MHz, DMSO-d6): δ 165.94, 160.01, 147.20 (q, J 
= 3.8 Hz), 136.86 (q, J = 3.4 Hz), 133.29, 131.32, 128.23 (q, J = 33.0 Hz), 128.09, 126.83, 
122.63 (q, J = 273.2 Hz), 122.18, 50.34, 33.76. 
 
Synthesis of 4-fluoro-N-(2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethyl)benzamide (8)  
The title compound was obtained as a colourless solid in 67% yield (219 mg, 0.6 mmol) from 
6 (254 mg, 0.87 mmol) and 4-fluorobenzoyl chloride (0.25 ml, 2.0 mmol) according to the 
general procedure. Mp 164-167 °C. Rf = 0.1 (1:99 MeOH:CH2Cl2). 1H NMR (300 MHz, 
DMSO-d6): δ 9.12 – 8.95 (m, 1H), 8.47 (dd, J = 8.0, 2.3 Hz, 2H), 8.22 (m, 1H), 7.75 – 7.58 
(m, 2H), 7.32 – 7.10 (m, 2H), 3.89 (t, J = 6.1 Hz, 2H), 3.64 (q, J = 5.9 Hz, 2H). 13C NMR (75 
MHz, DMSO-d6): δ 164.78, 163.95 (d, J = 248.8 Hz), 160.05 (d, J = 160.9 Hz), 147.17 (q, J = 
3.8 Hz), 136.85 (q, J = 3.4 Hz), 129.67 (d, J = 2.9 Hz), 129.49 (d, J = 9.1 Hz), 128.15 (q, J = 
32.9 Hz), 122.61 (q, J = 273.2 Hz), 122.13, 115.03 (d, J = 21.8 Hz), 50.22, 33.87. 
 
Synthesis of N-(2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethyl)isobutyramide (9)  
The title compound was obtained as a colourless solid in 42% yield (119 mg, 0.36 mmol) 
from 6 (255 mg, 0.87 mmol) and isobutyryl chloride (0.21 ml, 2.0 mmol) according to the 
general procedure. Mp 162-165 °C. Rf = 0.17 (2:98 MeOH:CH2Cl2). 1H NMR (300 MHz, 
DMSO-d6): δ 9.24 (s, 1H), 8.62 (dd, J = 8.4, 1.7 Hz, 1H), 8.26 (d, J = 8.2 Hz, 1H), 7.83 (t, J = 
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5.7 Hz, 1H), 3.69 (t, J = 6.5 Hz, 2H), 3.41 (q, J = 6.3 Hz, 2H), 2.07 (h, J = 6.9 Hz, 1H), 0.85 
(d, J = 6.9 Hz, 6H). 13C NMR (75 MHz, DMSO-d6): δ 176.20, 160.01, 147.39 (q, J = 3.9 Hz), 
137.08 (q, J = 3.5 Hz), 128.48 (q, J = 33.0 Hz), 122.82 (q, J = 273.3 Hz), 122.28, 50.66, 
33.69, 32.83, 19.17. 
 
Synthesis of N-(2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethyl)pivalamide (10)  
The title compound was obtained as a colourless solid in 53% yield (163 mg, 0.48 mmol) 
from 6 (263 mg, 0.9 mmol) and pivaloyl chloride (0.22 ml, 2.0 mmol) according to the 
general procedure. Mp 172-174 °C. Rf = 0.25 (1.5:98.5 MeOH:CH2Cl2). 1H NMR (300 MHz, 
DMSO-d6): δ 9.25 (s, 1H), 8.62 (dd, J = 8.5, 1.9 Hz, 1H), 8.26 (d, J = 8.2 Hz, 1H), 7.55 (t, J = 
5.4 Hz, 1H), 3.70 (t, J = 6.6 Hz, 2H), 3.42 (q, J = 6.5 Hz, 2H), 0.93 (s, 9H). 13C NMR (75 
MHz, DMSO-d6): δ 177.61, 159.95, 147.42 (q, J = 3.8 Hz), 137.10 (q, J = 3.6 Hz), 128.51 (q, 
J = 33.0 Hz), 122.81 (q, J = 273.2 Hz), 122.30, 50.63, 37.82, 33.16, 27.06. 
 
Synthesis of N-(2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethyl)-2-naphthamide (11) 
The title compound was obtained as a colourless solid in 48% yield (163 mg, 0.4 mmol) from 
6 (268 mg, 0.92 mmol) and pivaloyl chloride (0.22 ml, 2.0 mmol) according to the general 
procedure. Mp 176-178 °C. Rf = 0.14 (1:99 MeOH:CH2Cl2). 1H NMR (300 MHz, DMSO-d6): 
δ 9.05 (s, 1H), 8.66 (t, J = 4.8 Hz, 1H), 8.46 (d, J = 8.0 Hz, 1H), 8.27 (d, J = 8.2 Hz, 1H), 8.19 
(s, 1H), 7.92 (dd, J = 11.9, 7.9 Hz, 3H), 7.76 – 7.52 (m, 3H), 3.94 (t, J = 6.0 Hz, 2H), 3.72 (q, 
J = 5.6 Hz, 2H). 13C NMR (75 MHz, DMSO-d6): δ 165.98, 160.29 – 159.58 (m), 147.19 (q, J 
= 3.8 Hz), 136.84 (q, J = 3.4 Hz), 134.17, 131.92, 130.63, 128.75, 128.19 (q, J = 33.1 Hz), 
127.74, 127.63, 127.53, 127.28, 126.66, 123.61, 122.50 (q, J = 273.4 Hz), 122.18, 50.38, 
33.88. 
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Synthesis of N-(2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethyl)adamantane-1-
carboxamide (12) 
The title compound was obtained as a colourless solid in 94% yield (339 mg, 0.81 mmol) 
from 6 (254 mg, 0.87 mmol) and l-adamantanecarbonyl chloride (400 mg, 2.0 mmol) 
according to the general procedure. Mp 185-186 °C. Rf = 0.25 (5:95 MeOH:CH2Cl2). 1H 
NMR (400 MHz, CDCl3): δ 9.00 (s, 1H), 8.25 (s, 2H), 6.42 (t, 1H), 3.79 (q, J = 5.8 Hz, 2H), 
3.71 – 3.59 (m, 2H), 2.02 (s, 3H), 1.80 (s, 6H), 1.77 – 1.62 (m, 6H). 13C NMR (101 MHz, 
CDCl3): δ 178.36, 160.48, 147.44 (q, J = 3.8 Hz), 136.16 (q, J = 3.3 Hz), 130.41 (q, J = 33.9 
Hz), 122.51 (q, J = 273.4 Hz), 121.93, 51.90, 40.69, 39.13, 36.54, 33.12, 28.13. 
 
 
Synthesis of N-(2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethyl)furan-2-carboxamide 
(13) 
The title compound was obtained as a colourless solid in 83% yield (252 mg, 0.72 mmol) 
from 6 (254 mg, 0.87 mmol) and 2-furoyl chloride (0.20 ml, 2.0 mmol) according to the 
general procedure. Mp 129-131 °C. Rf = 0.27 (5:95 MeOH:CH2Cl2). 1H NMR (400 MHz, 
CDCl3): δ 8.92 (s, 1H), 8.45 – 8.01 (m, 2H), 7.41 (s, 1H), 7.05 (d, J = 3.4 Hz, 1H), 6.95 (t, 
1H), 6.60 – 6.41 (m, 1H), 4.01 – 3.92 (m, 2H), 3.84 – 3.71 (m, 2H). 13C NMR (101 MHz, 
CDCl3): δ 160.61, 158.33, 147.48 – 147.17 (m), 144.3, 136.04 (q, J = 3.4 Hz), 130.30 (q, J = 
33.8 Hz), 122.48 (q, J = 273.5 Hz), 121.89, 114.89, 112.38, 51.93, 33.29. 
 
Synthesis of 4-methoxy-N-(2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethyl)benzamide 
(14) 
The title compound was obtained as a colourless solid in 82% yield (275 mg, 0.7 mmol) from 
6 (254 mg, 0.87 mmol) and 4-methoxybenzoyl chloride (0.27 ml, 2.0 mmol) according to the 
general procedure. Mp 167-168 °C. Rf = 0.22 (5:95 MeOH:CH2Cl2). 1H NMR (300 MHz, 
DMSO-d6): δ 9.04 (s, 1H), 8.46 (dd, J = 8.3, 1.8 Hz, 1H), 8.29 (t, J = 5.3 Hz, 1H), 8.22 (d, J = 
8.2 Hz, 1H), 7.55 (d, J = 8.9 Hz, 2H), 6.89 (d, J = 8.9 Hz, 2H), 3.87 (t, J = 6.2 Hz, 2H), 3.78 
(s, 3H), 3.62 (q, J = 6.0 Hz, 2H). 13C NMR (75 MHz, DMSO-d6): δ 165.38, 161.66, 160.03, 
147.14 (q, J = 3.7 Hz), 136.81 (q, J = 3.3 Hz), 128.66, 128.13 (q, J = 33.0 Hz), 125.47, 122.63 
(q, J = 273.3 Hz), 122.10, 113.27, 55.26, 50.39, 33.73. 
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Synthesis of N-(2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethyl)nicotinamide (15) 
The title compound was obtained as a colourless solid in 69% yield (214 mg, 0.6 mmol) from 
6 (254 mg, 0.87 mmol) and nicotinoyl chloride (356 mg, 2.0 mmol) according to the general 
procedure. Mp 174-176 °C. Rf = 0.26 (10:90 MeOH:CH2Cl2). 1H NMR (400 MHz, DMSO-
d6): δ 9.08 (s, 1H), 8.80 – 8.73 (m, 1H), 8.73 – 8.62 (m, 2H), 8.55 – 8.45 (m, 1H), 8.25 (d, J = 
8.2 Hz, 1H), 7.94 (m, 1H), 7.42 (m, 1H), 3.90 (t, J = 6.2 Hz, 2H), 3.67 (q, J = 5.9 Hz, 2H). 13C 
NMR (101 MHz, DMSO-d6): δ 164.52, 160.02, 151.98, 148.0, 147.20 (q, J = 3.6 Hz), 136.89 
(q, J = 3.3 Hz), 134.53, 128.7, 128.23 (q, J = 33.1 Hz), 123.23, 122.58 (q, J = 273.4 Hz), 
122.18, 50.16, 33.76. 
 
Synthesis of 2-phenoxy-N-(2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethyl)acetamide 
(16) 
The title compound was obtained as a colourless solid in 73% yield (202 mg, 0.52 mmol) 
from 6 (206 mg, 0.71 mmol) and phenoxyacetyl chloride (0.22 ml, 1.6 mmol) according to the 
general procedure. Mp 126-129 °C. Rf = 0.24 (5:95 MeOH:CH2Cl2). 1H NMR (300 MHz, 
DMSO-d6): δ 9.22 (s, 1H), 8.57 (dd, J = 8.2, 1.8 Hz, 1H), 8.26 (d, J = 8.2 Hz, 1H), 8.14 (t, J = 
5.6 Hz, 1H), 7.28 (dd, J = 8.6, 7.4 Hz, 2H), 7.05 – 6.81 (m, 3H), 4.28 (s, 2H), 3.77 (t, J = 6.6 
Hz, 2H), 3.54 (q, J = 6.4 Hz, 2H). 13C NMR (75 MHz, DMSO-d6): δ 167.75, 159.85, 157.37, 
147.36 (q, J = 3.8 Hz), 137.06 (q, J = 3.5 Hz), 129.45, 128.49 (q, J = 33.1 Hz), 122.73 (q, J = 
273.3 Hz), 122.32, 121.27, 114.65, 66.61, 50.48, 32.58. 
 
5.3 Second-generation analogue  
5.3.1 Synthesis of intermediates 
Synthesis of 2-((5-(trifluoromethyl)pyridin-2-yl)thio)ethanaminium chloride (47) 
A mixture of 4 (680 mg, 2.1 mmol) and HCl in dioxane (17 mL) was stirred at room 
temperature for 3 hours. The suspension was diluted with Et2O (17 mL) and stirred for 10 
minutes. The resulting precipitate was filtered, rinsed with Et2O (10 mL) and the solid was 
collected. The residual solvent was removed under reduced pressure and the solid was dried 
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under reduced pressure overnight. The compound 47 was obtained as a colourless solid in 
98% yield (535 mg, 2.0 mmol) and used without further purification.  
 
Synthesis of 2-((5-(trifluoromethyl)pyridin-2-yl)thio)ethanamine (48) 
To a stirred solution of 47 (530 mg, 2.05 mmol) in dry THF (30 mL) at 0 °C was added Et3N 
(1.8 mL, 10.5 mmol). To this solution, 4-fluorobenzoyl chloride (0.62 mL, 5.3 mmol) was 
added dropwise. The mixture was stirred at room temperature for 1 hour, then poured into 
water (100 mL) and extracted with EtOAc (3 x 40 mL). The combined organic phases were 
washed with saturated aqueous NH4Cl (3 x 40 mL), water (40 mL), brine (40 mL), dried 
(MgSO4) and evaporated under reduced pressure. The crude product was purified using 
column chromatography on silica gel with 1-5% MeOH in CH2Cl2 as eluent to afford 48 as a 
colourless solid in 68% yield. Mp 115-118 °C. Rf = 0.4. 1H NMR (400 MHz, CDCl3): δ 8.63 
(s, 1H), 7.95 – 7.60 (m, 3H), 7.34 (d, J = 8.3 Hz, 1H), 7.23 (s, 1H), 7.06 (m, 2H), 3.79 (q, J = 
5.6 Hz, 2H), 3.49 (t, J = 6.1 Hz, 2H). 
 
Synthesis of 4-fluoro-N-methyl-N-(2-((5-(trifluoromethyl)pyridin-2-
yl)thio)ethyl)benzamide (49) 
To a stirred solution of 48 (450 mg, 1.3 mmol) in dry THF (5 mL) at room temperature was 
added a 60% dispersion of NaH in mineral oil (68 mg, 1.7 mmol). After 10 minutes, the MeI 
(0.8 mL, 13.0 mmol) was added to the mixture and stirred at 40 °C for 5 hours. The reaction 
was quenched with saturated aqueous NH4Cl (2 mL), extracted with Et2O (30 mL) and the 
organic layer was washed with brine (10 mL). The crude product was purified using column 
chromatography on silica gel to afford 49 as a colourless solid in 83% yield. Mp 86-88 °C. Rf 
= 0.15 (2:3 EtOAc:hexane). 1H NMR (400 MHz, CDCl3): δ 8.53 (d, J = 115.9 Hz, 1H), 7.96 – 
6.34 (m, 6H), 4.31 – 3.16 (m, 4H), 3.08 (s, 3H). 
5.3.2 Synthesis of the second-generation analogue  
Synthesis of 4-fluoro-N-methyl-N-(2-((5-(trifluoromethyl)pyridin-2-
yl)sulfonyl)ethyl)benzamide (23) 
To a stirred solution of 49 (336 mg, 0.93 mmol) in acetone and water (4:1, 3 mL) was added 
Oxone™  (2.25 g, 3.66 mmol), and the mixture was stirred overnight before evaporating the 
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acetone under reduced pressure. The remaining aqueous suspension was poured into water 
(10 mL) and extracted with EtOAc (2 x 30 mL). The organic layer was washed with brine (10 
mL) and dried (MgSO4). The crude product was purified using column chromatography on 
silica gel and dried under reduced pressure overnight. The title compound 23 was afforded in 
67% yield (243 mg, 0.62 mmol) as a colourless solid. Mp 119-122 °C. Rf = 0.24 (3:2 
EtOAc:hexane). 1H NMR (400 MHz, CDCl3): δ 8.99 (s, 1H), 8.24 (s, 2H), 7.50 – 7.34 (m, 
2H), 7.08 (m, 2H), 3.92 (d, J = 52.1 Hz, 4H), 3.09 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 
171.01, 163.63 (d, J = 250.6 Hz), 160.46, 147.91 – 146.71 (m), 136.84 – 135.36 (m), 131.63 
(d, J = 3.5 Hz), 130.34 (q, J = 34.0 Hz), 129.49 (d, J = 6.8 Hz), 122.53 (q, J = 273.5 Hz), 
121.96, 115.66 (d, J = 21.9 Hz), 49.34, 42.46, 39.05. 
 
5.4 Synthesis of intermediates from the sixth approach 
Synthesis of 2-(4-fluoro-N-methylbenzamido)ethyl 4-fluorobenzoate (42) 
To a solution of 2-(methylamino)ethanol 40 (0.4 ml, 5.0 mmol) and pyridine (4 mL, 50 
mmol) in dry THF (20 mL) was added 4-fluorobenzoyl chloride 41 (3 mL, 25.0 mmol) at 0 
°C. The mixture was stirred at room temperature overnight and monitored with TLC. Upon 
completion, the reaction was poured into saturated aqueous NH4Cl (60 mL) and extracted 
with EtOAc (3 x 40 mL). The combined organic phases were washed with saturated aqueous 
NH4Cl (3 x 40 mL), saturated aqueous NaHCO3 (3 x 40 mL), brine (40 mL) and dried 
(MgSO4). The crude product was purified using column chromatography on silica gel to 
afford 42 as a colourless solid in 91% yield. Rf = 0.16 (7:3 EtOAc:hexane). 1H NMR (300 
MHz, CDCl3): δ 8.25 – 7.87 (m, 2H), 7.39 (dd, J = 8.4, 5.3 Hz, 2H), 7.20 – 6.96 (m, 4H), 4.88 
– 4.28 (m, 2H), 4.09 – 3.63 (m, 2H), 3.11 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 167.70, 
165.06, 164.33, 161.75, 132.31 (d, J = 9.5 Hz), 132.17 (d, J = 3.5 Hz), 129.30 (d, J = 8.4 Hz), 
126.10, 115.71 (dd, J = 21.9, 12.9 Hz), 62.22, 46.94, 38.99. 
 
Synthesis of 4-fluoro-N-(2-hydroxyethyl)-N-methylbenzamide (43) 
Compound 42 (1.00 g, 3.15 mmol) was dissolved in MeOH (20 mL), and K2CO3 (2.0 g, 14.7 
mmol) was added. The reaction was stirred at room temperature for 45 minutes and monitored 
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with TLC. Upon completion, the mixture was poured into water (100 mL), extracted with 
EtOAc (6 x 30 mL), washed with water (3 x 30 mL), dried (Na2SO4) and the solvent was 
evaporated under reduced pressure. The crude product was purified using column 
chromatography on silica gel with 10% EtOH in EtOAc as eluent, to afford 43 as a colourless 
oil in 45% yield. Rf = 0.24. 1H NMR (400 MHz, CDCl3): δ 7.43 (s, 2H), 7.06 (s, 2H), 4.03 – 
3.29 (m, 5H), 3.03 (s, 3H).  
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6 Appendix 
6.1 Spectra of prepared analogues and their intermediates 
1H and 13C NMR spectra of compound 4 
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69 
1H and 13C NMR spectra of compound 5 
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1H, 13C and DEPT135 spectra of compound CV3 
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73 
1H, 13C and DEPT135 spectra of compound 7 
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75 
1H, 13C and DEPT135 spectra of compound 8 
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77 
1H, 13C and DEPT135 spectra of compound 9 
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79 
1H, 13C and DEPT135 spectra of compound 10 
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81 
1H, 13C and DEPT135 spectra of compound 11 
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1H, 13C and DEPT135 spectra of compound 12 
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85 
1H, 13C and DEPT135 spectra of compound 13 
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87 
1H, 13C and DEPT135 spectra of compound 14 
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89 
1H, COSY45, 13C and DEPT135 NMR spectra of compound 15 
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91 
1H, 13C and DEPT135 spectra of 16 
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93 
1H-NMR spectrum of compound 48 
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94 
1H-NMR spectrum of compound 49  
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95 
1H, 13C and DEPT135 spectra of compound 23 
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6.2 Spectra of intermediates from attempted approaches 
1H and 13C NMR spectra of compound 25 
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99 
1H, 13C and DEPT135 NMR spectra of compound 30 
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1H, 13C and DEPT135 spectra of compound 42 
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1H NMR spectrum of compound 43 
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